Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
99mTc-3PRGD2 SPECT/CT in esophageal cancer
NCT02744729Phase 1Completed
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Oct 2015
- Primary completion
- Jan 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of 99mTc-3PRGD2 in esophageal cancer, sponsored by The First Hospital of Fujian Medical University. Primary endpoints: Visual Assessment of Esophagus Lesions in 99mTc-3PRGD2 SPECT/CT Scan at 1 year and Semiquantitative Assessment of Esophagus Lesions in 99mTc-3PRGD2 SPECT/CT Scan at 1 year. Started Oct 2015; status: completed.
02
Drugs
99mTc-3PRGD2
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT02744729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02744729.